Serum biomarkers to evaluate the integrity of the neurovascular unit

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Biomarkers have the potential to enable the clinicians to screen infants for brain injury, monitor progression of disease, identify injured brain regions, assess efficacy of neuroprotective therapies, and offer hope to identify the timing of the injury, thus shedding light on the potential pathophysiology and the most effective therapy. Currently, clinicians do not routinely use biomarkers to care for neonates with Neonatal Encephalopathy (NE) and brain injury due to prenatal hypoxia-asphyxia. This review will cover potential biomarkers of the neurovascular unit in the setting of NE that (i) can help assess the degree or severity of encephalopathy at birth; (ii) can help monitor progression of disease process and efficacy of neuroprotective therapy; (iii) can help assess neurodevelopmental outcome. These biomarkers will be summarized in two categories: 1) Specific biomarkers targeting the neurovascular unit such as glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), S100B, and neuron specific enolase (NSE) and 2) general inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1b (IL-1b), and pNF-H, among others.

Original languageEnglish (US)
Pages (from-to)707-711
Number of pages5
JournalEarly Human Development
Volume90
Issue number10
DOIs
StatePublished - 2014

Fingerprint

Biomarkers
Brain Diseases
Serum
Phosphopyruvate Hydratase
Brain Injuries
Disease Progression
Interleukins
Asphyxia
Glial Fibrillary Acidic Protein
Hydrolases
Ubiquitin
Interleukin-6
Therapeutics
Parturition
Newborn Infant
Cytokines
Wounds and Injuries
Brain

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Serum biomarkers to evaluate the integrity of the neurovascular unit. / Mir, Imran N.; Chalak, Lina F.

In: Early Human Development, Vol. 90, No. 10, 2014, p. 707-711.

Research output: Contribution to journalArticle

@article{55807764f8a0499d8e6fb0f61df2f967,
title = "Serum biomarkers to evaluate the integrity of the neurovascular unit",
abstract = "Biomarkers have the potential to enable the clinicians to screen infants for brain injury, monitor progression of disease, identify injured brain regions, assess efficacy of neuroprotective therapies, and offer hope to identify the timing of the injury, thus shedding light on the potential pathophysiology and the most effective therapy. Currently, clinicians do not routinely use biomarkers to care for neonates with Neonatal Encephalopathy (NE) and brain injury due to prenatal hypoxia-asphyxia. This review will cover potential biomarkers of the neurovascular unit in the setting of NE that (i) can help assess the degree or severity of encephalopathy at birth; (ii) can help monitor progression of disease process and efficacy of neuroprotective therapy; (iii) can help assess neurodevelopmental outcome. These biomarkers will be summarized in two categories: 1) Specific biomarkers targeting the neurovascular unit such as glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), S100B, and neuron specific enolase (NSE) and 2) general inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1b (IL-1b), and pNF-H, among others.",
author = "Mir, {Imran N.} and Chalak, {Lina F.}",
year = "2014",
doi = "10.1016/j.earlhumdev.2014.06.010",
language = "English (US)",
volume = "90",
pages = "707--711",
journal = "Early Human Development",
issn = "0378-3782",
publisher = "Elsevier Ireland Ltd",
number = "10",

}

TY - JOUR

T1 - Serum biomarkers to evaluate the integrity of the neurovascular unit

AU - Mir, Imran N.

AU - Chalak, Lina F.

PY - 2014

Y1 - 2014

N2 - Biomarkers have the potential to enable the clinicians to screen infants for brain injury, monitor progression of disease, identify injured brain regions, assess efficacy of neuroprotective therapies, and offer hope to identify the timing of the injury, thus shedding light on the potential pathophysiology and the most effective therapy. Currently, clinicians do not routinely use biomarkers to care for neonates with Neonatal Encephalopathy (NE) and brain injury due to prenatal hypoxia-asphyxia. This review will cover potential biomarkers of the neurovascular unit in the setting of NE that (i) can help assess the degree or severity of encephalopathy at birth; (ii) can help monitor progression of disease process and efficacy of neuroprotective therapy; (iii) can help assess neurodevelopmental outcome. These biomarkers will be summarized in two categories: 1) Specific biomarkers targeting the neurovascular unit such as glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), S100B, and neuron specific enolase (NSE) and 2) general inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1b (IL-1b), and pNF-H, among others.

AB - Biomarkers have the potential to enable the clinicians to screen infants for brain injury, monitor progression of disease, identify injured brain regions, assess efficacy of neuroprotective therapies, and offer hope to identify the timing of the injury, thus shedding light on the potential pathophysiology and the most effective therapy. Currently, clinicians do not routinely use biomarkers to care for neonates with Neonatal Encephalopathy (NE) and brain injury due to prenatal hypoxia-asphyxia. This review will cover potential biomarkers of the neurovascular unit in the setting of NE that (i) can help assess the degree or severity of encephalopathy at birth; (ii) can help monitor progression of disease process and efficacy of neuroprotective therapy; (iii) can help assess neurodevelopmental outcome. These biomarkers will be summarized in two categories: 1) Specific biomarkers targeting the neurovascular unit such as glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), S100B, and neuron specific enolase (NSE) and 2) general inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1b (IL-1b), and pNF-H, among others.

UR - http://www.scopus.com/inward/record.url?scp=84922402610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922402610&partnerID=8YFLogxK

U2 - 10.1016/j.earlhumdev.2014.06.010

DO - 10.1016/j.earlhumdev.2014.06.010

M3 - Article

C2 - 25064445

AN - SCOPUS:84922402610

VL - 90

SP - 707

EP - 711

JO - Early Human Development

JF - Early Human Development

SN - 0378-3782

IS - 10

ER -